Apixaban and Eptifibatide: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Aug 8, 2026 · Source data updated Jul 11, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Apixaban
Eptifibatide
No brand names on record
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Both of these medicines make it harder for your blood to clot, just in different ways. Apixaban (Eliquis) is a blood thinner, and eptifibatide stops platelets from sticking together. Used together, their effects add up, so there is a higher chance of bleeding. Sometimes that bleeding can be serious.
The good news is that your care team uses these two together on purpose in certain situations, and they watch you closely when they do. Watch for warning signs like unusual bruising, pink or red urine, black stools, coughing or vomiting blood, or bleeding that will not stop. If any of these happen, get medical help right away. Never stop either medicine on your own, talk with your doctor or pharmacist first.
Mechanism: Additive pharmacodynamic effect on hemostasis. Apixaban is a direct factor Xa inhibitor; eptifibatide is a GPIIb/IIIa antagonist that blocks platelet aggregation. Neither is a prodrug, so the effect is straightforwardly additive antithrombotic activity, not a PK change.
- Direction: Increased bleeding risk (increased combined effect).
- Severity/Evidence: Major; evidence is theoretical/additive.
- Onset: Unspecified.
- Management: Monitor closely for bleeding; evaluate any signs of blood loss promptly. Discontinue apixaban for active pathologic hemorrhage. Apixaban PD effect persists at least 24 hours; a specific anti-Xa reversal agent exists, and PCC, aPCC, or rFVIIa may be considered. Clotting assays are not useful to guide PCC use.
What happens
Increased risk of bleeding and can cause serious, potentially fatal bleeding
Interaction Deep Dive
Using apixaban together with antiplatelet drugs raises the likelihood of bleeding 1. In any patient receiving both anticoagulants and antiplatelet agents, any indication or symptom of blood loss should be assessed without delay 2. If active pathological hemorrhage occurs, apixaban should be stopped. Patients should be counseled about the signs and symptoms of blood loss and instructed to report them right away or seek emergency care. Apixaban should be halted in patients experiencing active pathological hemorrhage. There is a reversal agent available for the anti-factor Xa activity of apixaban. Apixaban's pharmacodynamic action can be anticipated to continue for a minimum of 24 hours following the final dose. Options that may be considered include prothrombin complex concentrate (PCC), activated prothrombin complex concentrate, or recombinant factor VIIa. If PCCs are administered, it is neither helpful nor recommended to track apixaban's anticoagulant effect through a clotting assay (PT, INR, or aPTT) or anti-factor Xa (FXa) activity. Activated oral charcoal decreases apixaban absorption, which in turn diminishes apixaban plasma concentration 1.
Why it happens (mechanism)
Additive effects on hemostasis
How to manage this interaction
These drugs are sometimes combined intentionally, and your care team manages the added bleeding risk with close monitoring.
- Keep taking both exactly as prescribed unless your prescriber tells you otherwise.
- Learn the signs of bleeding: unexpected bruising, red or pink urine, black or bloody stools, vomiting or coughing up blood, severe headache, or bleeding that will not stop.
- Report any of these right away, or go to an emergency room.
- Your team may check on you more often and can adjust care if needed. Reversal agents are available if a serious bleed occurs.
Ask your pharmacist or doctor any questions about what to watch for.
Management is individual — confirm any change with your pharmacist or prescriber.
Literature reports
3 reports — tap to read
a) A clinical study involving high-risk patients after acute coronary syndrome who were treated with aspirin or with aspirin plus clopidogrel (APPRAISE-2) was stopped ahead of schedule because bleeding occurred more frequently with apixaban than with placebo. Among patients on single antiplatelet therapy, the rate of ISTH major bleeding was 2.8% per year with apixaban versus 0.6% per year with placebo, and among those on dual antiplatelet therapy it was 5.9% per year with apixaban versus 2.5% per year with placebo 1.
b) In a clinical trial (ARISTOTLE) involving patients taking apixaban, the addition of aspirin raised the bleeding risk from 1.8% per year to 3.4% per year, while the addition of both aspirin and warfarin raised the bleeding risk from 2.7% per year to 4.6% per year; the use of dual antiplatelet therapy alongside apixaban in this trial was limited (2.3%) 1.
c) In a retrospective study, combining direct oral anticoagulant (DOAC) therapy with antiplatelet therapy (APT; n=78) versus DOAC therapy by itself (n=329) did not produce a significant change in the rate of major bleeding (1.3% vs 1.2%) or clinically relevant non-major bleeding (10.2% vs 6.4%) across 6 months of treatment. The patients were mainly Caucasian men whose mean age was 63.7 years. Those on concurrent APT had significantly higher mean body mass index (30.7 vs 28.4), higher mean CHA2DS2-VASc score (4.28 vs 3.85), and a greater likelihood of having diabetes (26.9% vs 17.3%) than those given DOAC monotherapy. The DOACs were prescribed for VTE treatment or atrial fibrillation and consisted of apixaban (58.5%), rivaroxaban (38.1%), and dabigatran (3.4%). Single antiplatelet therapy was used in 94.9% (74 patients), with aspirin 81 mg once daily being the most frequent regimen (69 patients). Additional APT regimens comprised aspirin 81 mg twice daily (3 patients), aspirin 325 mg daily (1 patient), clopidogrel 75 mg daily (1 patient), and dual APT with aspirin 81 mg and clopidogrel 75 mg daily (4 patients) 3.
Common questions
Can I take Apixaban and Eptifibatide together?
Taking apixaban and eptifibatide together adds up their blood-thinning effects and raises bleeding risk, so watch closely for any signs of bleeding and report them right away. Do not stop either medicine on your own. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Apixaban and Eptifibatide interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Apixaban and Eptifibatide interaction managed?
These drugs are sometimes combined intentionally, and your care team manages the added bleeding risk with close monitoring. Keep taking both exactly as prescribed unless your prescriber tells you otherwise. Learn the signs of bleeding: unexpected bruising, red or pink urine, black or bloody stools, vomiting or coughing up blood, severe headache, or bleeding that will not stop. Report any of these… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
From our Q&A
Real reader questions about these medications, each personally answered by our pharmacist:
Questions for your pharmacist
- Does my dose of Apixaban or Eptifibatide need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (3)
- Product Information: ELIQUIS(R) oral film coated tablets, apixaban oral film coated tablets. Bristol-Myers Squibb Company (per Dailymed), Princeton, NJ, 2024. DailyMed
- Product Information: SAVAYSA(R) oral tablets, edoxaban oral tablets. Daiichi Sankyo Inc (per FDA), Basking Ridge, NJ, 2023. DailyMed
- Tinkham TT, Vazquez SR, Jones AE, et al: Direct oral anticoagulant plus antiplatelet therapy: prescribing practices and bleeding outcomes. J Thromb Thrombolysis 2020; 49(3):492-496. PubMed
Keep reading about Apixaban
Keep reading about Eptifibatide
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist